Tau (tubulin-associated unit) protein is one of the two hallmarks of Alzheimer’s disease, besides β-Amyloid (1-42)(Abeta42). The Elecsys Total-Tau CSF assay is designed to detect the six human brain Tau isoforms or fragments in human CSF.
Many studies show that total Tau CSF (tTau) levels increase around 2 – 3 fold in mild moderate Alzheimer’s Disease patients compared to age matched controls while CSF β Amyloid (1 42) levels decrease to around half the level in controls.1,2 CSF tTau has been shown to reflect the intensity of the neuronal and axonal damage and degeneration. High CSF tTau is also associated with a faster progression from Mild Cognitive Impairment (MCI) to AD.3
Elecsys® Total-Tau CSF (tTau) is an in vitro diagnostic immunoassay intended for the quantitative determination of the total tau protein concentration in human cerebrospinal fluid (CSF).4
Elecsys® tTau assay is part of the Elecsys® AD portfolio, along with Elecsys® β-Amyloid(1-42) CSF II (AB42 2) and Elecsys® Phospho-Tau (181P) CSF (pTau) immunoassays.4
Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.5,6
Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.4,6